Cited by 860Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentBone health and treatments

The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.

Open access

Eisenberger, Mario A., Blumenstein, Brent A., Crawford, E. David, Miller, Gary, McLeod, David G., Loehrer, Patrick J., Wilding, George, Sears, Kathy, Culkin, Daniel J., Thompson, Ian M., Bueschen, Anton J., Lowe, Bruce A.·1998·New England Journal of Medicine

DOI 10.1056/nejm199810083391504

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Combined androgen blockade for the treatment of metastatic prostate cancer consists of an antiandrogen drug plus castration. In a previous trial, we found that adding the antiandrogen flutamide to leuprolide acetate (a synthetic gonadotropin-releasing hormone that results in medical ablation of testicular function) significantly improved survival as compared with that achieved with placebo plus leuprolide acetate. In the current trial, we compared flutamide plus bilateral orchiectomy with placebo plus orchiectomy. METHODS: We randomly assigned patients who had never received antiandrogen therapy and who had distant metastases from adenocarcinoma of the prostate to treatment with bilateral orchiectomy and either flutamide or placebo. Patients were stratified according to the extent of disease and according to performance status. RESULTS: Of the 1387 patients who were enrolled in the trial, 700 were randomly assigned to the flutamide group and 687 to the placebo group. Overall, the incidence of toxic effects was minimal; the only notable differences between the groups were the greater rates of diarrhea and anemia with flutamide. There was no significant difference between the two groups in overall survival (P=0.14). The estimated risk of death (hazard ratio) for flutamide as compared with placebo was 0.91 (90 percent confidence interval, 0.81 to 1.01). Flutamide was not associated with enhanced benefit in patients with minimal disease. CONCLUSIONS: The addition of flutamide to bilateral orchiectomy does not result in a clinically meaningful improvement in survival among patients with metastatic prostate cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199810083391504

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Studies on Prostatic Cancer: I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate
Huggins, C., & Hodges, C. V. (2002) · The Journal of Urology · doi:10.1016/s0022-5347(05)64820-3 · Cited by 3,856
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Surrogate endpoints in clinical trials: Definition and operational criteria
Prentice, R. L. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080407 · Cited by 2,057
Cancer statistics, 1997
Parker, S. L., Tong, T., Bolden, S., & Wingo, P. A. (1997) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.47.1.5 · Cited by 2,000
A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., & Goodman, P. J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908173210702 · Cited by 1,464
Self-citation
Leuprolide versus Diethylstilbestrol for Metastatic Prostate Cancer
The Leuprolide Study Group (1984) · New England Journal of Medicine · doi:10.1056/nejm198411153112004 · Cited by 622
The veterans administration cooperative urological research group's studies of cancer of the prostate
Byar, D. P. (1973) · Cancer · doi:10.1002/1097-0142(197311)32:5 · Cited by 595
Designs for group sequential tests
Fleming, T. R., Harrington, D. P., & O’Brien, P. C. (1984) · Controlled Clinical Trials · doi:10.1016/s0197-2456(84)80014-8 · Cited by 354
Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients
Prostate Cancer Trialists' Collaborative Group (1995) · The Lancet · doi:10.1016/s0140-6736(95)92163-x · Cited by 320
Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation
Rubinstein, L., Gail, M. H., & Santner, T. J. (1981) · Journal of Chronic Diseases · doi:10.1016/0021-9681(81)90007-2 · Cited by 270

Show all 25 references

Research works printed but not linked: 3

Huggins C, 1941, Cancer Res, 1, 293
10.1002/1097-0142(19931215)72:12+<3834::AID-CNCR2820721714>3.0.CO;2-Z · DOI
Eisenberger MA, 1994, Semin Oncol, 21, 613

Sorted by citations

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer
Petrylak, D. P., Tangen, C. M., Hussain, M., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D. L., Moinpour, C. M., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665
Self-citation
Natural History of Progression After PSA Elevation Following Radical Prostatectomy
Pound, C. R. (1999) · JAMA · doi:10.1001/jama.281.17.1591 · Cited by 3,077
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Sweeney, C. J., Chen, Y., Carducci, M. A., Liu, G., Jarrard, D. F., Eisenberger, M. A., Wong, Y., Hahn, N. M., Kohli, M., Cooney, M. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503747 · Cited by 2,958
Self-citation
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Fizazi, K. S., Tran, N., Fein, L. E., Matsubara, N., Rodríguez-Antolín, A., Alekseev, B. Y., Özgüroğlu, M., Ye, D., Feyerabend, S., Protheroe, A. S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704174 · Cited by 2,326
Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
Scher, H. I., Halabi, S., Tannock, I. F., Morris, M. J., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C. S., Bubley, G. J., Dreicer, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4487 · Cited by 2,228
Self-citation
Noninvasive detection of clinically occult lymph-node metastases in prostate cancer
Harisinghani, M. G., Barentsz, J., Hahn, P. F., Deserno, W. M., Tabatabaei, S., van de Kaa, C. H., de la Rosette, J., & Weissleder, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022749 · Cited by 1,971
Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients
Bubendorf, L., Schöpfer, A., Wagner, U., Sauter, G., Moch, H., Willi, N., Gasser, T. C., & Mihatsch, M. J. (2000) · Human Pathology · doi:10.1053/hp.2000.6698 · Cited by 1,895
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Fizazi, K. S., Scher, H. I., Molina, A., Logothetis, C. J., Chi, K. N., Jones, R. J., Staffurth, J. N., North, S. A., Vogelzang, N. J., Fred Saad, C., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70379-0 · Cited by 1,389
Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy and Pelvic Lymphadenectomy in Men with Node-Positive Prostate Cancer
Messing, E. M., Manola, J. B., Sarosdy, M., Wilding, G., Crawford, E. D., & Trump, D. L. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912093412401 · Cited by 1,178
Self-citation
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
Kyriakopoulos, C. E., Chen, Y., Carducci, M. A., Liu, G., Jarrard, D. F., Hahn, N. M., Shevrin, D. H., Dreicer, R., Hussain, M., Eisenberger, M. A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3657 · Cited by 1,108
Self-citation
Androgen Deprivation Therapy for Prostate Cancer
Sharifi, N. (2005) · JAMA · doi:10.1001/jama.294.2.238 · Cited by 1,087
Increased Expression of Genes Converting Adrenal Androgens to Testosterone in Androgen-Independent Prostate Cancer
Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4000 · Cited by 1,082
Prostate Cancer
Nelson, W. G., Marzo, A. M. D., & Isaacs, W. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021562 · Cited by 951
Adjuvant Radiotherapy for Pathologically Advanced Prostate Cancer
Thompson, I. M., Tangen, C. M., Paradelo, J. C., Lucia, M. S., Miller, G. J., Troyer, D. A., Messing, E. M., Forman, J. D., Chin, J. L., Swanson, G. P., et al. (2006) · JAMA · doi:10.1001/jama.296.19.2329 · Cited by 897
Self-citation
Guidelines on Prostate Cancer
Heidenreich, A., Joaquim Bellmunt, B., Bolla, M., Joniau, S., Matveev, V. B., Mottet, N., Wiegel, T., & Zattoni, F. (2013) · Cited by 869
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials
Dalesio, O., van Tinteren, H., Clarke, M., Peto, R., Schroder, F., Dechering, I., Evans, V., Godwin, J., Blumenstein, B., Crawford, E., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02163-2 · Cited by 815
Self-citation
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
Gravis, G., Fizazi, K. S., Joly, F., Oudard, S. M., Priou, F., Esterni, B., Latorzeff, I., Delva, R., Krakowski, I., Laguerre, B., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70560-0 · Cited by 746
Biology of Prostate-Specific Antigen
Balk, S. P., Ko, Y.-J., & Bubley, G. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.083 · Cited by 730
The Androgen Axis in Recurrent Prostate Cancer
Mohler, J. L., Gregory, C. W., Ford, O. H., Kim, D., Weaver, C. M., Petrusz, P., Wilson, E. M., & French, F. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1146-03 · Cited by 675
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Horwich, A., Parker, C. C., Bangma, C., & Kataja, V. V. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq174 · Cited by 602
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
Taplin, M., Bubley, G. J., Ko, Y., Small, E. J., Upton, M. P., Rajeshkumar, B. R., & Balk, S. P. (1999) · PubMed · Cited by 594
Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants
Mostaghel, E. A., Marck, B. T., Plymate, S. R., Vessella, R. L., Balk, S. P., Matsumoto, A. M., Nelson, P. S., & Montgomery, B. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0728 · Cited by 591
Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
Hussain, M., Tangen, C. M., Berry, D. L., Higano, C. S., Crawford, E. D., Liu, G., Wilding, G., Prescott, S. M., Sundaram, S. K., Small, E. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212299 · Cited by 580
Self-citation
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial
Gravis, G., Boher, J., Joly, F., Soulie, M., Albiges, L. K., Priou, F., Latorzeff, I., Delva, R., Krakowski, I., Laguerre, B., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.11.005 · Cited by 463
The Current State of Hormonal Therapy for Prostate Cancer
Hellerstedt, B. A., & Pienta, K. J. (2002) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.52.3.154 · Cited by 386
Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis
Yuan, X., Cai, C., Chen, S., Chen, S., Yu, Z., & Balk, S. P. (2013) · Oncogene · doi:10.1038/onc.2013.235 · Cited by 378
Androgen Receptor Mutations in Androgen-Independent Prostate Cancer: Cancer and Leukemia Group B Study 9663
Taplin, M., Rajeshkumar, B. R., Halabi, S., Werner, C. P., Woda, B. A., Picus, J., Stadler, W. M., Hayes, D. F., Kantoff, P. W., Vogelzang, N. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.102 · Cited by 364
Cellular and molecular mechanisms of action of bisphosphonates
Rogers, M. J., Gordon, S., Benford, H. L., Coxon, F. P., Luckman, S. P., Mönkkönen, J., & Frith, J. C. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12+ · Cited by 982
PROSTATE SPECIFIC ANTIGEN ONLY PROGRESSION OF PROSTATE CANCER
Moul, J. W. (2000) · The Journal of Urology · doi:10.1016/s0022-5347(05)67511-8 · Cited by 350
Beta-catenin affects androgen receptor transcriptional activity and ligand specificity.
Truica, C. I., Byers, S. W., & Gelmann, E. P. (2000) · PubMed · Cited by 346
Positron emission tomography for prostate, bladder, and renal cancer
Schöder, H. M., & Larson, S. M. (2004) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2004.06.004 · Cited by 334
Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target
Chen, Y., Clegg, N. J., & Scher, H. I. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70229-3 · Cited by 322
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
Gillessen, S., Omlin, A. G., Attard, G., Bono, J. S. D., Efstathiou, E., Fizazi, K. S., Halabi, S., Nelson, P. S., Sartor, O. A., Smith, M. R., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv257 · Cited by 325
Antidepressant-Induced Sexual Dysfunction
Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., & Khan, Z. M. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a195 · Cited by 320
Androgen deprivation therapy for prostate cancer: Current status and future prospects
Miyamoto, H., Messing, E. M., & Chang, C. (2004) · The Prostate · doi:10.1002/pros.20115 · Cited by 318
Expression of Concern: Up‐regulation of Wnt‐1 and β‐catenin production in patients with advanced metastatic prostate carcinoma
Chen, G., Shukeir, N., Potti, A., Sircar, K., Aprikian, A., Goltzman, D., & Rabbani, S. A. (2004) · Cancer · doi:10.1002/cncr.20518 · Cited by 283
Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making
Oefelein, M. G., Feng, A. H., SCOLIERI, M. J., Ricchiutti, D., & Resnick, M. I. (2000) · Urology · doi:10.1016/s0090-4295(00)00793-7 · Cited by 279
The natural history of metastatic progression in men with prostate‐specific antigen recurrence after radical prostatectomy: long‐term follow‐up
Antonarakis, E. S., Feng, Z., Trock, B. J., Humphreys, E. B., Carducci, M. A., Partin, A. W., Walsh, P. C., & Eisenberger, M. A. (2011) · British Journal of Urology · doi:10.1111/j.1464-410x.2011.10422.x · Cited by 276
Self-citation
PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance
Hsieh, A., & Edlind, M. P. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.122876 · Cited by 285
Evaluation of Prostate-Specific Antigen Declines for Surrogacy in Patients Treated on SWOG 99-16
Petrylak, D. P., Ankerst, D. P., Jiang, C. S., Tangen, C. M., Hussain, M., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Kohli, M., et al. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj129 · Cited by 274
Self-citation
Cytoreductive Radical Prostatectomy in Patients with Prostate Cancer and Low Volume Skeletal Metastases: Results of a Feasibility and Case-Control Study
Heidenreich, A., Pfister, D. J. K. P., & Porres, D. (2014) · The Journal of Urology · doi:10.1016/j.juro.2014.09.089 · Cited by 269
Contemporary Role of Androgen Deprivation Therapy for Prostate Cancer
Pagliarulo, V., Sergio Bracarda, A., Eisenberger, M. A., Mottet, N., Schröder, F. H., Sternberg, C. N., & Studer, U. E. (2011) · European Urology · doi:10.1016/j.eururo.2011.08.026 · Cited by 265
Self-citation
Androgen receptor as a target in androgen-independent prostate cancer
Balk, S. P. (2002) · Urology · doi:10.1016/s0090-4295(02)01593-5 · Cited by 264
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
He, Y., Xu, W., Xiao, Y., Huang, H., Gu, D., & Ren, S. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01042-7 · Cited by 287
Systematic review and meta‐analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma
Samson, D. J., Seidenfeld, J., Schmitt, B. P., Hasselblad, V., Albertsen, P. C., Bennett, C. L., Wilt, T. J., & Aronson, N. (2002) · Cancer · doi:10.1002/cncr.10647 · Cited by 256
Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies
Gravis, G., Boher, J., Chen, Y., Liu, G., Fizazi, K. S., Carducci, M. A., Oudard, S. M., Joly, F., Jarrard, D. M., Soulie, M., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.02.001 · Cited by 252
Self-citation
Quality-of-Life Outcomes After Primary Androgen Deprivation Therapy: Results From the Prostate Cancer Outcomes Study
Potosky, A. L., Knopf, K., Clegg, L. X., Albertsen, P. C., Stanford, J. L., Hamilton, A. S., Gilliland, F. D., Eley, J. W., Stephenson, R. A., & Hoffman, R. M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.17.3750 · Cited by 251
THE BIOLOGY OF HORMONE REFRACTORY PROSTATE CANCER
Jt, I. (1999) · Urologic Clinics of North America · doi:10.1016/s0094-0143(05)70066-5 · Cited by 250
Beyond the Development of Health-Related Quality-of-Life (HRQOL) Measures: A Checklist for Evaluating HRQOL Outcomes in Cancer Clinical Trials—Does HRQOL Evaluation in Prostate Cancer Research Inform Clinical Decision Making?
Efficace, F., Bottomley, A., Osoba, D., Gotay, C. C., Flechtner, H., D’haese, S., & Zurlo, A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.121 · Cited by 247
Androgen receptors in prostate cancer.
Čulig, Z., Klocker, H., Bartsch, G., & Hobisch, A. (2002) · Endocrine Related Cancer · doi:10.1677/erc.0.0090155 · Cited by 247
Comparison of Survival Outcomes Among Cancer Patients Treated In and Out of Clinical Trials
Unger, J. M., Barlow, W. E., Martin, D. P., Ramsey, S. D., LeBlanc, M. L., Etzioni, R., & Hershman, D. L. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju002 · Cited by 234
Changes in Androgen Receptor Nongenotropic Signaling Correlate with Transition of LNCaP Cells to Androgen Independence
Unni, E., Sun, S., Nan, B., McPhaul, M. J., Cheskis, B. J., Mancini, M. A., & Marcelli, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1121 · Cited by 233
The Influence of Androgen Deprivation Therapy on Dihydrotestosterone Levels in the Prostatic Tissue of Patients with Prostate Cancer
Nishiyama, T., Hashimoto, Y., & Takahashi, K. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0913 · Cited by 224
Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault.
Arnold, J. T., & Isaacs, J. T. (2002) · Endocrine Related Cancer · doi:10.1677/erc.0.0090061 · Cited by 214
Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer
Hoyle, A. P., Ali, A., James, N. D., Cook, A. D., Parker, C. C., Bono, J. S. D., Attard, G., Chowdhury, S., Cross, W. R., Dearnaley, D. P., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.08.006 · Cited by 202
Drug Insight: role of the androgen receptor in the development and progression of prostate cancer
Taplin, M. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0765 · Cited by 199
Metastatic Carcinoma of the Prostate: Identifying Prognostic Groups Using Recursive Partitioning
Glass, T. R., Tangen, C. M., Crawford, E. D., & Thompson, I. M. (2003) · The Journal of Urology · doi:10.1016/s0022-5347(05)64059-1 · Cited by 192
Self-citation
The role of androgens and the androgen receptor in prostate cancer.
Debes, J. D., & Tindall, D. J. (2002) · Cancer Letters · doi:10.1016/s0304-3835(02)00413-5 · Cited by 191
American Society of Clinical Oncology Recommendations for the Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer
Loblaw, D. A., Mendelson, D. S., Talcott, J. A., Virgo, K. S., Somerfield, M. R., Ben‐Josef, E., Middleton, R., Porterfield, H. A., Sharp, S. A., Smith, T. J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.579 · Cited by 189
DHEA, Important Source of Sex Steroids in Men and Even More in Women
Labrie, F. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)82004-7 · Cited by 187
Prospective Trial of the Herbal Supplement PC-SPES in Patients With Progressive Prostate Cancer
Small, E. J., Frohlich, M. W., Bok, R., Shinohara, K., Grossfeld, G. D., Rozenblat, Z., Kelly, W. K., Corry, M., & Reese, D. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.21.3595 · Cited by 181
Assessing Meaningful Change in Quality of Life Over Time: A Users' Guide for Clinicians
Sprangers, M. A. G., Moinpour, C. M., Moynihan, T. J., Patrick, D. L., & Revicki, D. A. (2002) · Mayo Clinic Proceedings · doi:10.4065/77.6.561 · Cited by 176
Progress in active specific immunotherapy of prostate cancer
Tjoa, B. A., & Murphy, G. P. (2000) · Seminars in Surgical Oncology · doi:10.1002/(sici)1098-2388(200001/02)18:1 · Cited by 31
National Comprehensive Cancer Network guidelines for the management of prostate cancer
Scherr, D. S., Swindle, P., & Scardino, P. T. (2003) · Urology · doi:10.1016/s0090-4295(02)02395-6 · Cited by 170
Osteoporosis in Men Treated With Androgen Deprivation Therapy for Prostate Cancer
Ross, R. W., & Small, E. J. (2002) · The Journal of Urology · doi:10.1016/s0022-5347(05)65060-4 · Cited by 166
Association of African-American Ethnic Background With Survival in Men With Metastatic Prostate Cancer
Thompson, I. M., Tangen, C. M., Tolcher, A. W., Crawford, E. D., Eisenberger, M. A., & Moinpour, C. M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.3.219 · Cited by 166
Self-citation
Expression of the gastrin‐releasing peptide receptor, the prostate stem cell antigen and the prostate‐specific membrane antigen in lymph node and bone metastases of prostate cancer
Ananias, H. J. K., van den Heuvel, M. C., Helfrich, W., & de Jong, I. J. (2009) · The Prostate · doi:10.1002/pros.20957 · Cited by 165
FAILURE TO ACHIEVE CASTRATE LEVELS OF TESTOSTERONE DURING LUTEINIZING HORMONE RELEASING HORMONE AGONIST THERAPY: THE CASE FOR MONITORING SERUM TESTOSTERONE AND A TREATMENT DECISION ALGORITHM
Oefelein, M. G., & Cornum, R. L. (2000) · The Journal of Urology · doi:10.1016/s0022-5347(05)67290-4 · Cited by 165
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Horwich, A., Parker, C. C., de Reijke, T. M., & Kataja, V. V. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt208 · Cited by 158
Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases
Schick, U., Jorcano, S., Nouet, P., Rouzaud, M., Vees, H., Zilli, T., Ratib, O. M., Weber, D. C., & Miralbell, R. (2013) · Acta Oncologica · doi:10.3109/0284186x.2013.764010 · Cited by 156
ANDROGEN RECEPTOR GENE AMPLIFICATION AT PRIMARY PROGRESSION PREDICTS RESPONSE TO COMBINED ANDROGEN BLOCKADE AS SECOND LINE THERAPY FOR ADVANCED PROSTATE CANCER
Palmberg, C., Koivisto, P. A., Kakkola, L., Tammela, T. L. J., Kallioniemi, O., & Visakorpi, T. (2000) · The Journal of Urology · doi:10.1016/s0022-5347(05)66935-2 · Cited by 152
Anaemia increases the risk of dementia in cognitively intact elderly
Atti, A. R., Palmer, K., Volpato, S., Zuliani, G., Winblad, B. G., & Fratiglioni, L. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.02.007 · Cited by 152
Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer
Lamont, K. R., & Tindall, D. J. (2011) · Molecular Endocrinology · doi:10.1210/me.2010-0469 · Cited by 150
Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial
Sydes, M. R., Parmar, M., James, N. D., Clarke, N. W., Dearnaley, D. P., Mason, M. D., Morgan, R. C., Sanders, K., & Royston, P. J. (2009) · Trials · doi:10.1186/1745-6215-10-39 · Cited by 150
Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens
Crawford, E. D., Schellhammer, P. F., McLeod, D. G., Moul, J. W., Higano, C. S., Shore, N. D., Denis, L., Iversen, P., Eisenberger, M. A., & Labrie, F. (2018) · The Journal of Urology · doi:10.1016/j.juro.2018.04.083 · Cited by 152
Self-citation
Studies on molecular mechanisms of growth inhibitory effects of thymoquinone against prostate cancer cells: role of reactive oxygen species
Koka, P. S., Mondal, D., Schultz, M., Abdel‐Mageed, A. B., & Agrawal, K. C. (2010) · Experimental Biology and Medicine · doi:10.1258/ebm.2010.009369 · Cited by 147
Bicalutamide Monotherapy Versus Flutamide Plus Goserelin in Prostate Cancer Patients: Results of an Italian Prostate Cancer Project Study
Boccardo, F., RUBAGOTTI, A., Barichello, M., Battaglia, M., CARMIGNANI, G., Comeri, G., Conti, G. N., Cruciani, G., Dammino, S., Delliponti, U., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2027 · Cited by 146
Prostate cancer: ESMO Consensus Conference Guidelines 2012
Horwich, A., Hugosson, J., de Reijke, T. M., Wiegel, T., Fizazi, K. S., Kataja, V. V., Parker, C. C., Joaquim Bellmunt, B., Berthold, D., Bill‐Axelson, A., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds624 · Cited by 147
Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails
Niu, Y., Chang, T.-M., Yeh, S., Ma, W., Wang, Y. Z., & Chang, C. (2010) · Oncogene · doi:10.1038/onc.2010.121 · Cited by 146
Targeting the stromal androgen receptor in primary prostate tumors at earlier stages
Niu, Y., Altuwaijri, S., Yeh, S., Lai, K., Yu, S., Chuang, K., Huang, S., Lardy, H. A., & Chang, C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804701105 · Cited by 143
Antiandrogen withdrawal in castrate‐refractory prostate cancer
Sartor, O. A., Tangen, C. M., Hussain, M., Eisenberger, M. A., Parab, M., Fontana, J. A., Chapman, R., Mills, G. M., Raghavan, D., & Crawford, E. D. (2008) · Cancer · doi:10.1002/cncr.23473 · Cited by 142
Self-citation
Osteoporosis in Men Treated With Androgen Deprivation Therapy for Prostate Cancer
Ross, R. W., & Small, E. J. (2002) · The Journal of Urology · doi:10.1097/00005392-200205000-00003 · Cited by 142
Development of GnRH Antagonists for Prostate Cancer: New Approaches to Treatment
Cook, T. M., & Sheridan, W. P. (2000) · The Oncologist · doi:10.1634/theoncologist.5-2-162 · Cited by 140
Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer
Ross, R. W., Xie, W., Regan, M. M., Pomerantz, M. M., Nakabayashi, M., Daskivich, T. J., Sartor, O. A., Taplin, M., Kantoff, P. W., & Oh, W. K. (2008) · Cancer · doi:10.1002/cncr.23304 · Cited by 139
ASC-J9 Suppresses Castration-Resistant Prostate Cancer Growth through Degradation of Full-length and Splice Variant Androgen Receptors
Yamashita, S., Lai, K.-P., Chuang, K., Xu, D., Miyamoto, H., Tochigi, T., Pang, S., Li, L., Arai, Y., Kung, H.-J., et al. (2012) · Neoplasia · doi:10.1593/neo.111436 · Cited by 139
HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study
Hearn, J. W. D., AbuAli, G., Reichard, C. A., Reddy, C. A., Magi‐Galluzzi, C., Chang, K., Carlson, R. E., Rangel, L. J., Reagan, K., Davis, B. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30227-3 · Cited by 140
Galectin-3 Regulates Mitochondrial Stability and Antiapoptotic Function in Response to Anticancer Drug in Prostate Cancer
Fukumori, T., Oka, N., Takenaka, Y., Nangia‐Makker, P., Elsamman, E., Kasai, T., Shono, M., Kanayama, H.-O., Ellerhorst, J. A., Lotan, R., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3750 · Cited by 133
Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death
Wen, S., Niu, Y., Lee, S. O., & Chang, C. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.07.008 · Cited by 134
Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review
Schmitt, B. P., Wilt, T. J., Schellhammer, P. F., DeMasi, V., Sartor, O. A., Crawford, E. D., & Bennett, C. L. (2001) · Urology · doi:10.1016/s0090-4295(00)01086-4 · Cited by 131
Self-citation
The Endocrinology of Prostate Cancer
Taplin, M. E., & Ho, S. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7782 · Cited by 130
Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth
Yamamoto, Y., Loriot, Y., Beraldi, E., Zhang, F., Wyatt, A. W., Nakouzi, N. A., Mo, F., Zhou, T., Kim, Y., Monia, B. P., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1108 · Cited by 129
Chemotherapy for prostate cancer
Gilligan, T. D., & Kantoff, P. W. (2002) · Urology · doi:10.1016/s0090-4295(02)01583-2 · Cited by 127
Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model
Gravis, G., Boher, J., Fizazi, K. S., Joly, F., Priou, F., Marino, P., Latorzeff, I., Delva, R., Krakowski, I., Laguerre, B., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.09.022 · Cited by 126
Elevated E2F1 Inhibits Transcription of the Androgen Receptor in Metastatic Hormone-Resistant Prostate Cancer
Davis, J. N., Wojno, K. J., Daignault, S. D., Hofer, M. D., Kuefer, R., Rubin, M. A., & Day, M. L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2497 · Cited by 125
All-trans retinoic acid and interferon-α in the treatment of a patient with resistant metastatic osteosarcoma
Todesco, A., Carli, M., Iacona, I., Frascella, E., Ninfo, V., & Rosolen, A. (2000) · Cancer · doi:10.1002/1097-0142(20001215)89:12 · Cited by 26
Actions of estrogens and endocrine disrupting chemicals on human prostate stem/progenitor cells and prostate cancer risk
Hu, W.-Y., Shi, G., Hu, D.-P., Nelles, J. L., & Prins, G. S. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.08.032 · Cited by 118
Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis
Tucci, M., Bertaglia, V., Vignani, F., Buttigliero, C., Fiori, C., Porpiglia, F., Scagliotti, G. V., & Maïo, M. D. (2015) · European Urology · doi:10.1016/j.eururo.2015.09.013 · Cited by 121
Bypass Mechanisms of the Androgen Receptor Pathway in Therapy-Resistant Prostate Cancer Cell Models
Marques, R. B., Dits, N. F. J., Erkens‐Schulze, S., van Weerden, W. M., & Jenster, G. W. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013500 · Cited by 124

Authors: Eisenberger, M. A., Blumenstein, B. A., Crawford, E. D., Miller, G., McLeod, D. G., Loehrer, P. J., Wilding, G., Sears, K., Culkin, D. J., Thompson, I. M., Bueschen, A. J., & Lowe, B. A.
Affiliations: Johns Hopkins Hospital (US)
SWOG Cancer Research Network (US)
University of Colorado Denver (US)
Walter Reed National Military Medical Center (US)
University of Wisconsin–Madison (US)
University of Oklahoma Health Sciences Center (US)
University of Alabama at Birmingham (US)
Oregon Health & Science University (US)
ORCID: Eisenberger, Mario A.
Blumenstein, Brent A.
Crawford, E. David
McLeod, David G.
Loehrer, Patrick J.
Wilding, George
Culkin, Daniel J.
Thompson, Ian M.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1998-10-08
Volume: 339
Issue: 15
Pages: 1036-1042
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199810083391504
OpenAlex: W2003985632
Cited by: 859
References: 25
Citations by year: 2026: 2 · 2025: 5 · 2024: 8 · 2023: 12 · 2022: 20 · 2021: 15 · 2020: 21 · 2019: 26 · 2018: 25 · 2017: 23 · 2016: 34 · 2015: 52 · 2014: 49 · 2013: 51 · 2012: 37
FWCI: 37.16
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (2u10ca038926-25)
National Cancer Institute (CA-32102, CA 42777, U10CA032102, U10CA042777, CA 38926)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords: metastatic prostate cancer, bilateral orchiectomy, flutamide, combined androgen blockade, leuprolide, antiandrogen therapy, overall survival, adverse effects, anemia, diarrhea
MeSH terms: Adenocarcinoma, Adult, Aged, Aged, 80 and over, Androgen Antagonists, Bone Neoplasms, Combined Modality Therapy, Double-Blind Method, Flutamide, Humans, Male, Middle Aged, Orchiectomy, Prostatic Neoplasms, Soft Tissue Neoplasms, Survival Analysis, Prostate-Specific Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks